PURPOSE: Neuroinflammation plays a critical role in various neuropathological conditions, and hence there is renewed interest in the translocator protein (TSPO) as a biomarker of microglial activation and macrophage infiltration in the brain. This is reflected in the large amount of research conducted seeking to replace the prototypical PET radiotracer (11)C-R-PK11195 with a TSPO ligand with higher performance. Here we report the in vivo preclinical investigation of the novel TSPO tracer (18)F-GE-180 in a rat model of stroke. METHODS: Focal cerebral ischaemia was induced in Wistar rats by 60-min occlusion of the middle cerebral artery (MCAO). Brain damage was assessed 24 h after MCAO by T2 MRI. Rats were scanned with (11)C-R-PK11195 and (18)F-GE-180 5 or 6 days after MCAO. Specificity of binding was confirmed by injection of unlabelled R-PK11195 or GE-180 20 min after injection of (18)F-GE-180. In vivo data were confirmed by ex vivo immunohistochemistry for microglial (CD11b) and astrocytic biomarkers (GFAP). RESULTS: (18)F-GE-180 uptake was 24 % higher in the core of the ischaemic lesion and 18 % lower in the contralateral healthy tissue than that of (11)C-R-PK11195 uptake (1.5 ± 0.2-fold higher signal to noise ratio). We confirmed this finding using the simplified reference tissue model (BPND = 3.5 ± 0.4 and 2.4 ± 0.5 for (18)F-GE-180 and (11)C-R-PK11195, respectively, with R 1 = 1). Injection of unlabelled R-PK11195 or GE-180 20 min after injection of (18)F-GE-180 significantly displaced (18)F-GE-180 (69 ± 5 % and 63 ± 4 %, respectively). Specificity of the binding was also confirmed by in vitro autoradiography, and the location and presence of activated microglia and infiltrated macrophages were confirmed by immunohistochemistry. CONCLUSION: The in vivo binding characteristics of (18)F-GE-180 demonstrate a better signal to noise ratio than (11)C-R-PK11195 due to both a better signal in the lesion and lower nonspecific binding in healthy tissue. These results provide evidence that (18)F-GE-180 is a strong candidate to replace (11)C-R-PK11195.
PURPOSE: Neuroinflammation plays a critical role in various neuropathological conditions, and hence there is renewed interest in the translocator protein (TSPO) as a biomarker of microglial activation and macrophage infiltration in the brain. This is reflected in the large amount of research conducted seeking to replace the prototypical PET radiotracer (11)C-R-PK11195 with a TSPO ligand with higher performance. Here we report the in vivo preclinical investigation of the novel TSPO tracer (18)F-GE-180 in a rat model of stroke. METHODS: Focal cerebral ischaemia was induced in Wistar rats by 60-min occlusion of the middle cerebral artery (MCAO). Brain damage was assessed 24 h after MCAO by T2 MRI. Rats were scanned with (11)C-R-PK11195 and (18)F-GE-180 5 or 6 days after MCAO. Specificity of binding was confirmed by injection of unlabelled R-PK11195 or GE-180 20 min after injection of (18)F-GE-180. In vivo data were confirmed by ex vivo immunohistochemistry for microglial (CD11b) and astrocytic biomarkers (GFAP). RESULTS: (18)F-GE-180 uptake was 24 % higher in the core of the ischaemic lesion and 18 % lower in the contralateral healthy tissue than that of (11)C-R-PK11195 uptake (1.5 ± 0.2-fold higher signal to noise ratio). We confirmed this finding using the simplified reference tissue model (BPND = 3.5 ± 0.4 and 2.4 ± 0.5 for (18)F-GE-180 and (11)C-R-PK11195, respectively, with R 1 = 1). Injection of unlabelled R-PK11195 or GE-180 20 min after injection of (18)F-GE-180 significantly displaced (18)F-GE-180 (69 ± 5 % and 63 ± 4 %, respectively). Specificity of the binding was also confirmed by in vitro autoradiography, and the location and presence of activated microglia and infiltrated macrophages were confirmed by immunohistochemistry. CONCLUSION: The in vivo binding characteristics of (18)F-GE-180 demonstrate a better signal to noise ratio than (11)C-R-PK11195 due to both a better signal in the lesion and lower nonspecific binding in healthy tissue. These results provide evidence that (18)F-GE-180 is a strong candidate to replace (11)C-R-PK11195.
Authors: Marc A Kropholler; Ronald Boellaard; Bart N M van Berckel; Alie Schuitemaker; Reina W Kloet; Mark J Lubberink; Cees Jonker; Philip Scheltens; Adriaan A Lammertsma Journal: J Cereb Blood Flow Metab Date: 2007-04-04 Impact factor: 6.200
Authors: Alex M Dickens; Susanne Vainio; Päivi Marjamäki; Jarkko Johansson; Paula Lehtiniemi; Johanna Rokka; Juha Rinne; Olof Solin; Merja Haaparanta-Solin; Paul A Jones; William Trigg; Daniel C Anthony; Laura Airas Journal: J Nucl Med Date: 2014-02-10 Impact factor: 10.057
Authors: C Cawthorne; C Prenant; A Smigova; P Julyan; R Maroy; K Herholz; N Rothwell; H Boutin Journal: Br J Pharmacol Date: 2011-02 Impact factor: 8.739
Authors: Hervé Boutin; Christian Prenant; Renaud Maroy; James Galea; Andrew D Greenhalgh; Alison Smigova; Christopher Cawthorne; Peter Julyan; Shane M Wilkinson; Samuel D Banister; Gavin Brown; Karl Herholz; Michael Kassiou; Nancy J Rothwell Journal: PLoS One Date: 2013-02-13 Impact factor: 3.240
Authors: Akihiro Takano; Fredrik Piehl; Jan Hillert; Andrea Varrone; Sangram Nag; Balázs Gulyás; Per Stenkrona; Victor L Villemagne; Christopher C Rowe; Richard Macdonell; Nabil Al Tawil; Thomas Kucinski; Torsten Zimmermann; Marcus Schultze-Mosgau; Andrea Thiele; Anja Hoffmann; Christer Halldin Journal: EJNMMI Res Date: 2013-04-24 Impact factor: 3.138
Authors: Ulrike W Kaunzner; Yeona Kang; Shun Zhang; Eric Morris; Yihao Yao; Sneha Pandya; Sandra M Hurtado Rua; Calvin Park; Kelly M Gillen; Thanh D Nguyen; Yi Wang; David Pitt; Susan A Gauthier Journal: Brain Date: 2019-01-01 Impact factor: 13.501
Authors: Paolo Zanotti-Fregonara; Mattia Veronese; Belen Pascual; Robert C Rostomily; Federico Turkheimer; Joseph C Masdeu Journal: Eur J Nucl Med Mol Imaging Date: 2019-01-17 Impact factor: 9.236
Authors: M Unterrainer; D F Fleischmann; F Vettermann; V Ruf; L Kaiser; D Nelwan; S Lindner; M Brendel; V Wenter; S Stöcklein; J Herms; V M Milenkovic; R Rupprecht; J C Tonn; C Belka; P Bartenstein; M Niyazi; N L Albert Journal: Eur J Nucl Med Mol Imaging Date: 2019-09-05 Impact factor: 9.236
Authors: Nathalie L Albert; M Unterrainer; D F Fleischmann; S Lindner; F Vettermann; A Brunegraf; L Vomacka; M Brendel; V Wenter; C Wetzel; R Rupprecht; J-C Tonn; C Belka; P Bartenstein; M Niyazi Journal: Eur J Nucl Med Mol Imaging Date: 2017-08-19 Impact factor: 9.236
Authors: Marcus Unterrainer; C Mahler; L Vomacka; S Lindner; J Havla; M Brendel; G Böning; B Ertl-Wagner; T Kümpfel; V M Milenkovic; R Rupprecht; M Kerschensteiner; P Bartenstein; Nathalie L Albert Journal: Eur J Nucl Med Mol Imaging Date: 2018-03-09 Impact factor: 9.236
Authors: Samira Parhizkar; Thomas Arzberger; Matthias Brendel; Gernot Kleinberger; Maximilian Deussing; Carola Focke; Brigitte Nuscher; Monica Xiong; Alireza Ghasemigharagoz; Natalie Katzmarski; Susanne Krasemann; Stefan F Lichtenthaler; Stephan A Müller; Alessio Colombo; Laura Sebastian Monasor; Sabina Tahirovic; Jochen Herms; Michael Willem; Nadine Pettkus; Oleg Butovsky; Peter Bartenstein; Dieter Edbauer; Axel Rominger; Ali Ertürk; Stefan A Grathwohl; Jonas J Neher; David M Holtzman; Melanie Meyer-Luehmann; Christian Haass Journal: Nat Neurosci Date: 2019-01-07 Impact factor: 24.884
Authors: Sujata Sridharan; Joel Raffel; Ashwini Nandoskar; Chris Record; David J Brooks; David Owen; David Sharp; Paolo A Muraro; Roger Gunn; Richard Nicholas Journal: Mol Imaging Biol Date: 2019-10 Impact factor: 3.488